Rascol O, Lees A J, Senard J M, Pirtosek Z, Montastruc J L, Fuell D
Service de Pharmacologie Médicale et Clinique, INSERM U317, Faculté de Médecine, Toulouse, France.
Clin Neuropharmacol. 1996 Jun;19(3):234-45. doi: 10.1097/00002826-199619030-00005.
Forty-six patients with Parkinson's disease experiencing motor fluctuations and not optimally controlled on levodopa received as adjunct therapy a new nonergoline dopamine agonist, ropinirole, in a 3-month randomized placebo-controlled trial. Ropinirole significantly reduced the duration of off periods as assessed by self-scoring diary cards. There were more nonserious dopaminergic adverse events in the ropinirole group. More patients withdrew because of adverse events or insufficient therapeutic effect in the placebo group. Ropinirole has beneficial adjuvant effects in parkinsonian patients with moderate motor disability and motor fluctuations.
46例帕金森病患者存在运动波动，左旋多巴治疗效果欠佳，在一项为期3个月的随机安慰剂对照试验中接受了一种新型非麦角多巴胺激动剂罗匹尼罗作为辅助治疗。通过自我评分日记卡评估，罗匹尼罗显著缩短了“关”期的时长。罗匹尼罗组出现的非严重多巴胺能不良事件更多。安慰剂组因不良事件或治疗效果不佳而退出试验的患者更多。罗匹尼罗对中度运动功能障碍和运动波动的帕金森病患者具有有益的辅助作用。
